NetworkNewsBreaks – Pressure BioSciences, Inc. (
Post# of 1354
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform solutions to the worldwide life sciences and other industries, today announced the award of a key U.S. patent entitled “Sample Preparation Devices and Methods.” According to the update, the new patent (U.S. 10,710,082) brings the company’s intellectual property (“IP”) estate up to a total of 25 issued patents. “We have many customers worldwide who routinely use our ‘PCT’ Micro-Pestle consumable in their research studies. These include Professor Phil Robinson and his team at the Children’s Medical Research Institute in Australia (processing 70,000 tumor samples, looking for prognostic and diagnostic markers in cancer) and Dr. Tiannan Guo and his team at Westlake University in China (studying thyroid cancer and COVID-19),” Pressure BioSciences’ Global Director of Sales and Marketing, Roxana McCloskey, said in the news release. “The PCT MP is also a critical part of the innovative laser microdissection tumor processing workflow developed by Dr. Tom Conrads of the Inova Health System in the U.S. This important new tumor processing method promises significant improvements in the clinical management of most solid tumor cancers. His novel workflow is the basis of our major co-marketing collaboration recently announced with Leica Microsystems (a Danaher Company). It is clear why we see this award of the PCT MP patent as a critical milestone in securing our pivotal intellectual property around the PCT system, and another important driver toward accelerated adoption of PCT in biological sample preparation markets. We expect to take full advantage of this opportunity and further boost our sales.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer